Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMT after Liver Transplant for HCC
NCT02702960Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of haploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil) in hepatocellular carcinoma (HCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Recurrence-Free Survival at 1 year. Planned start Mar 2016; status: withdrawn.
02
Drugs
haploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil)
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02702960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702960.